Table 1.

Demographic characteristics of SMA patients at baseline.

Distribution of patients-SMA type; n (%)	310 (100)
Type 1a	156 (50.3)
Type 1b	120 (38.7)
Type 1c	34 (11)
SMN copies; n (%)
2 copies	302 (97.4)
3 copies	8 (2.6)
Gender
Female; n (%)	162 (52.3)
Male; n (%)	148 (47.7)
Age at onset of SMA; mean + SD (range) in months	2.4 ± 1.1 (0–5)
Age at onset of treatment, median (range) in months	5 (1–120)
Monitoring time, median (range) in months	14 (2–48)
CHOP-INTEND score, at baseline; median (range)	16 (0–50)
CHOP-INTEND score, post-treatment; median (range)	28.0.5 (1–64)
Number of Nusinersen doses, median, (range)	5 (4–15)
Events of death during monitoring; n (%)	66 (21.3)
First year (%, within death)	(68.2)
Second year (%, within death)	(27.3)
Third year (%, within death)	(6.1)
Presymptomatic patients n (%)	7 (2.2)